London
· Delayed Price · Currency is GBP · Price in USD Syros Pharmaceuticals Statistics
Total Valuation
Syros Pharmaceuticals has a market cap or net worth of GBP 4.48 million. The enterprise value is 6.06 million.
| Market Cap | 4.48M |
| Enterprise Value | 6.06M |
Important Dates
The next estimated earnings date is Friday, February 28, 2025.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +31.77% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 13.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.08 |
| EV / Sales | 19.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.08 |
Financial Position
The company has a current ratio of 2.25
| Current Ratio | 2.25 |
| Quick Ratio | 2.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | -20.92 |
Financial Efficiency
Return on equity (ROE) is -776.96% and return on invested capital (ROIC) is -94.28%.
| Return on Equity (ROE) | -776.96% |
| Return on Assets (ROA) | -59.88% |
| Return on Capital (ROIC) | -94.28% |
| Revenue Per Employee | 4,235 |
| Profits Per Employee | -1.07M |
| Employee Count | 68 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -96.88% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 3.36 |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (20 Days) | 1,035,727 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, Syros Pharmaceuticals had revenue of GBP 287,995 and -72.98 million in losses. Loss per share was -1.98.
| Revenue | 287,995 |
| Gross Profit | -65.84M |
| Operating Income | -83.21M |
| Pretax Income | -72.98M |
| Net Income | -72.98M |
| EBITDA | -82.21M |
| EBIT | -83.21M |
| Loss Per Share | -1.98 |
Balance Sheet
The company has 43.48 million in cash and 44.93 million in debt, giving a net cash position of -1.46 million.
| Cash & Cash Equivalents | 43.48M |
| Total Debt | 44.93M |
| Net Cash | -1.46M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -8.30M |
| Book Value Per Share | -0.31 |
| Working Capital | 26.52M |
Cash Flow
In the last 12 months, operating cash flow was -74.62 million and capital expenditures -28,352, giving a free cash flow of -74.65 million.
| Operating Cash Flow | -74.62M |
| Capital Expenditures | -28,352 |
| Free Cash Flow | -74.65M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -28,891.67% |
| Pretax Margin | -25,340.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Syros Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.77% |
| Shareholder Yield | -31.77% |
| Earnings Yield | -1,630.05% |
| FCF Yield | -1,667.36% |
Stock Splits
The last stock split was on September 19, 2022. It was a reverse split with a ratio of 0.1.
| Last Split Date | Sep 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Syros Pharmaceuticals has an Altman Z-Score of -15.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.52 |
| Piotroski F-Score | n/a |